MedTech Terms
    The authoritative reference
    All terms
    Market SegmentsStrategic Landscape

    Molecular Diagnostics

    IVDs that detect nucleic acids - DNA or RNA - to diagnose disease.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Molecular diagnostics use PCR, isothermal amplification, sequencing (NGS), or hybridization to detect pathogens (HPV, HIV, respiratory panels), genetic variants (BRCA, KRAS), and oncology biomarkers (MRD, ctDNA). Technologies include PCR, isothermal amplification and next-generation sequencing. Uses span infectious disease, oncology, genetic testing and pharmacogenomics. Payment often depends on MolDX coverage policies and evidence of clinical utility.
    What the regulation says
    Molecular diagnostics, as a type of in vitro diagnostic (IVD) device, are subject to regulations such as the FDA's 21 CFR 809 and the EU In Vitro Diagnostic Regulation (IVDR) 2017/746. These regulations ensure the safety and effectiveness of molecular diagnostic tests, covering aspects from design and development to post-market surveillance. Specific guidance documents, like those from the FDA, detail requirements for analytical and clinical validity, as well as labeling.

    What this means in practice

    COVID accelerated decentralized PCR. Oncology MRD (Natera Signatera, Guardant Reveal) is reshaping post-treatment monitoring. Reimbursement via MolDx and PAMA price cuts shape unit economics.

    Examples

    • A PCR-based COVID-19 diagnostic test submitted for FDA Emergency Use Authorization (EUA) must demonstrate high sensitivity and specificity in detecting SARS-CoV-2 RNA.
    • A next-generation sequencing (NGS) panel used to identify oncology biomarkers for targeted therapy selection requires CE marking under the EU IVDR, necessitating a Notified Body assessment.
    • A molecular diagnostic system processing patient samples and transmitting results to an Electronic Health Record (EHR) must comply with HIPAA regulations for protected health information and implement cybersecurity controls per NIST CSF.
    Common pitfalls
    • •Misinterpreting genetic variants or pathogen strains can lead to inappropriate patient management or public health interventions.
    • •Failure to validate software algorithms used in molecular diagnostics can result in erroneous test results and patient harm.
    • •Lack of robust cybersecurity controls in connected molecular diagnostic devices can expose patient data or compromise test integrity.
    • •Using non-cGMP compliant reagents or instruments can invalidate test results and lead to regulatory non-compliance.
    • •Inadequate consideration of the total product lifecycle, including post-market surveillance, can lead to delayed identification of performance issues or adverse events.

    Frequently asked questions

    The primary challenge often involves demonstrating clear analytical and clinical validity, especially for companion diagnostics or tests with complex bioinformatics components. Regulators require robust evidence to support the intended use and performance claims.

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Ecosystems (1)

    Latest in MedTech

    Sources

    3 sources

    Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 4Trade press and expert commentary· 3
    Link health: 3 verified· last checked 2026-06-20
    AMP·1MedTech Europe·1MedTech Dive·1
    1. 1
      AMP
      Tier 4 Verified
      AMPamp.org
    2. 2
      MedTech Europe - Facts & Figures
      Tier 4 Verified
      MedTech Europemedtecheurope.org
    3. 3
      MedTech Dive
      Tier 4 Verified
      MedTech Divemedtechdive.com

    Inline markers like [1] jump to the matching reference above.